Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Bayer can absorb Roundup costs of 5 billion euros, but not 20 billion - Moody's

Published 30/04/2019, 10:34
Updated 30/04/2019, 10:35
© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen

© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen

BERLIN (Reuters) - Bayer (DE:BAYGN) could absorb litigation costs of up to 5 billion euros (£4.3 billion) to settle ongoing lawsuits linked to its Monsanto (NYSE:MON) weed-killer Roundup, credit rating agency Moody's said on Tuesday.

But if payouts reach 20 billion euros - a possible scenario according to analysts - the German pharmaceuticals company is in danger of losing its "Baa1" investment rating.

Claimants say that their cancer was caused by glyphosate, an ingredient in Roundup, and are demanding million-dollar compensation payments from Bayer, although some researchers contest this finding.

The World Health Organization in 2015 classified glyphosate as "probably carcinogenic to humans", but the U.S. Environmental Protection Agency in September 2017 concluded a decades-long assessment of glyphosate risks and found the chemical was not likely carcinogenic to humans.

In the United States alone there are 11,200 lawsuits pending against Monsanto, which Bayer bought last year for $63 billion, and litigation setbacks have sent Bayer shares plunging in recent months.

Moody's said that settlements involving payments totalling 20 billion euros made from 2020 until 2022 would lead to a leverage ratio above Bayer's current "Baa1" rating.

But if Bayer agreed to make the settlement payments by 2021 its leverage would increase to almost 4.0x which would even stretch even a hypothetical "Baa2" rating.

© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.